CDK6 as a predictive marker of response to fulvestrant treatment and a potential indicator of benefit from CDK4/6 inhibitor therapy in estrogen receptor-positive metastatic breast cancer

被引：0
|
作者：
Alves, C. [1 ]
Elias, D. [1 ]
Lyng, M. [1 ]
Bak, M. [2 ]
Lykkesfeldt, A. [3 ]
Ditzel, H. [1 ]
机构：
[1] Univ Southern Denmark, Canc & Inflammat Res, Odense, Denmark
[2] Univ Southern Denmark, Pathol, Odense, Denmark
[3] Danish Canc Soc, Res Ctr, Breast Canc Grp Cell Death & Metab, Copenhagen, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61416-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [41] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [42] Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
    Mohammadhadi Khorrami
    Vidya Sakar Viswanathan
    Priyanka Reddy
    Nathaniel Braman
    Siddharth Kunte
    Amit Gupta
    Jame Abraham
    Alberto J. Montero
    Anant Madabhushi
    npj Breast Cancer, 9
  • [43] MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
    Andrikopoulou, Angeliki
    Shalit, Almog
    Zografos, Eleni
    Koutsoukos, Konstantinos
    Korakiti, Anna-Maria
    Liontos, Michalis
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    CANCERS, 2021, 13 (16)
  • [44] Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
    Khorrami, Mohammadhadi
    Viswanathan, Vidya Sakar
    Reddy, Priyanka
    Braman, Nathaniel
    Kunte, Siddharth
    Gupta, Amit
    Abraham, Jame
    Montero, Alberto J.
    Madabhushi, Anant
    NPJ BREAST CANCER, 2023, 9 (01)
  • [45] Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit
    Lakkavalli, Rajeev Krishnappa
    Pehalajani, Jitendra Kumar
    Tirumala, Venkatesh
    Babu, Govind K.
    Loknatha, Dassappa
    Jacob, Linu Abraham
    Babu, Suresh M. C.
    Rudresha, A. H.
    Kadabur, Lokesh Nagendrappa
    Saldanha, Smitha C.
    Giri, G. V.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (04) : 994 - 997
  • [46] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [47] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [48] Efficacy of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors
    Mo, Hanjie
    Renna, Catherine E.
    Moore, Halle C. F.
    Abraham, Jame
    Kruse, Megan L.
    Montero, Alberto J.
    LeGrand, Susan B.
    Budd, G. Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
    Papadimitriou, Marios C.
    Pazaiti, Anastasia
    Iliakopoulos, Konstantinos
    Markouli, Mariam
    Michalaki, Vasiliki
    Papadimitriou, Christos A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2022, 1869 (12):
  • [50] Influence of the CDK4/6 Inhibitor Ribociclib on the peripheral Immune Response in Hormone Receptor Positive Breast Cancer
    Peuker, C. A.
    Yaghobramzi, S.
    Lueftner, D.
    Brucker, S.
    Decker, T.
    Fasching, P.
    Fehm, T.
    Janni, W.
    Kummel, S.
    Schneeweiss, A.
    Schuler, M.
    Busse, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E53 - E53
12345